A practical perspective on ulcerative colitis: patients' needs from aminosalicylate therapies

Area of Science:

• Gastroenterology
• Patient-Reported Outcomes
• Pharmacology

Background:

• Ulcerative colitis (UC) is a chronic inflammatory bowel disease.
• First-line therapies for UC often include aminosalicylates.
• Understanding patient experiences is crucial for treatment optimization.

Purpose of the Study:

• To investigate patient experiences with ulcerative colitis and first-line aminosalicylate therapies.
• To identify factors influencing patient satisfaction and treatment adherence.
• To understand patient preferences for ideal UC treatment.

Main Methods:

• An internet-based survey was distributed to a random sample of Crohn's and Colitis Foundation of America members with UC.
• 1,595 usable responses were collected and analyzed.
• Data included treatment satisfaction, remission rates, compliance, and ideal therapy characteristics.

Main Results:

• 43% of patients reported remission, but 74% experienced relapse in the past year.
• Over 60% were noncompliant with aminosalicylate dosing due to inconvenience.
• Key patient preferences for ideal treatment include high efficacy, oral dosing, fewer pills, less frequent dosing, and minimal side effects.

Conclusions:

• Continuous symptomatic remission is central to patient satisfaction in ulcerative colitis management.
• Current aminosalicylate therapies are perceived as inconvenient, leading to noncompliance.
• Development of convenient, effective oral therapies with fewer side effects could improve UC treatment outcomes.